As a monoclonal antibody, bevacizumab acts against the vascular endothelial growth factor (VEGF) and is usually indicated for cancer therapy; however, numerous investigations have supported the fundamental role of VEGF in acute lung injury (ALI) and ARDS, suggesting a potential role in the management of COVID-19 patients. Here, VEGFA is linked to COVID-19.